PIRAMAL PHARMA

BSE: 543635 21 Oct 2025

Healthcare

₹ 199.3

PIRAMAL PHARMA LIMITED specializes in Pharmaceuticals within the Healthcare sector.

PIRAMAL PHARMA

BSE: 543635 21 Oct 2025

Healthcare

₹ 199.3

PIRAMAL PHARMA LIMITED specializes in Pharmaceuticals within the Healthcare sector.

Book Value

61.3

Dividend Yield

0.07%

Debt to Equity

0.6

Stock P/E

289.0

Market Cap

24,954 Cr

PIRAMAL PHARMA - Share Price & Details

Market Cap

₹24,954

High /Low

308.0 / 180.0

Stock P/E

289.0

Book Value

₹61.3

Dividend Yield

0.07

ROCE

6.45

ROE

₹1.11

Face Value

10.0

PEG Ratio

-7.48

EVEBITDA

₹18.4

Debt

4,856

CMP / FCF

1,133

Debt to equity

₹0.6

NP Ann

91.1

High price all time

308.0

Piotroski score

₹7.0

Graham Number

32.0

No. Eq. Shares

133.0

Net CF

₹-36.9

Net profit

98.1

Price to book value

3.06

Interest Coverage

₹1.9

Low price all time

61.6

Industry PE

33.0

Reserves

₹6,801

Free Cash Flow

₹233

Broker Recommendations

Date	Author	Type	Reco Price	Target Price	Potential	Source	PDF Link
29 Jul 2025	ICICI Securities	Buy	₹205.65	₹265	34.4%	moneycontrol	View
29 Jul 2025	Motilal Oswal	Buy	₹205.65	₹240	21.8%	moneycontrol	View
29 May 2025	Motilal Oswal	Buy	₹205.75	₹250	21.2%	moneycontrol	View
15 May 2025	Motilal Oswal	Buy	₹208.55	₹250	21.7%	moneycontrol	View
24 Oct 2024	Motilal Oswal	Buy	₹256.4	₹310	14.7%	moneycontrol	View
25 Sep 2024	Motilal Oswal	Buy	₹226.45	₹260	-3.7%	moneycontrol	View
28 Jul 2024	ICICI Securities	Buy	₹166.5	₹200	-25.5%	moneycontrol	View
13 May 2024	ICICI Securities	Buy	₹154.35	₹190	-29.2%	moneycontrol	View
13 May 2024	Motilal Oswal	Buy	₹154.35	₹190	-29.2%	moneycontrol	View
13 May 2024	Asit C. Mehta	Buy	₹154.35	₹180	-32.9%	moneycontrol	View
01 Apr 2024	Asit C. Mehta	Buy	₹129.85	₹171	-36.3%	moneycontrol	View
01 Feb 2024	ICICI Securities	Buy	₹138.3	₹180	-32.9%	moneycontrol	View
31 Jan 2024	Motilal Oswal	Buy	₹144.2	₹165	-38.5%	moneycontrol	View

Price Chart

Volume Chart

Peer Comparison

Stock	Total Income	Net Profit	Net Sales	EPS	Market Cap (in Cr)	P/E
FABINO ENTERPRISES LIMITED	NA	NA	NA	NA	5.09	84.8
Triochem Products Ltd.,	2.21	-0.31	NA	-1.25	0
PIRAMAL PHARMA LIMITED	11508.0	1131.4	9698.8	0.85	24,954	289.0
Syngene International Limited	8159.0	740.0	7993.0	1.83	24557	48.4
PFIZER LTD.	6702.2	1917.5	6030.5	41.91	22558	147.0

Peer Comparison Chart

About PIRAMAL PHARMA

PIRAMAL PHARMA LIMITED, with Security Code 543635, is a leading player in the Pharmaceuticals industry, categorized under the Healthcare sector, offering Equity instruments.

Order Book

Latest News

Piramal Pharma - Kaynes Tech, Eternal among 8 F&O stocks that saw a high increase in futures open interest

(22 Sep 2025)

OI: 1,54,52500| Chg OI: 24,65000 | Chg OI (%): 18.98 Piramal Pharma.

Piramal Pharma Solutions boosts formulation development at Morpeth site with Korsch XM-12

(19 Sep 2025)

Piramal Pharma Solutions (PPS), a leading global Contract Development and Manufacturing Organization (CDMO) and part of Piramal Pharma Ltd.,...

From Compliance to Commitment: How Piramal Pharma is Reimagining Sustainability in Pharma

(18 Sep 2025)

In its fourth annual Sustainability Report, Piramal Pharma charts an evolution from foundational ESG reporting to embedding sustainability...

Divi’s, Piramal Pharma to Sai Life: Jefferies lists four pharma stocks to buy for up to 30% gains. Do you own any?

(15 Sep 2025)

India's CRDMO sector is set for growth in the next 3-5 years, with Jefferies highlighting four stocks including Divi's Labs, Sai Life are...

A Look At The Fair Value Of Piramal Pharma Limited (NSE:PPLPHARMA)

(10 Sep 2025)

Key Insights Piramal Pharma's estimated fair value is ₹173 based on 2 Stage Free Cash Flow to Equity With ₹198 share...

Piramal Pharma jumps 8%; JM Financial says 'Buy' stock, shares target price

(02 Sep 2025)

The Piramal Pharma stock rose 8 per cent to hit a high of Rs 201.45 apiece on BSE, trimming its 2025 losses to 22.7per cent.

Quarterly Table

Standalone Consolidated

Metrics	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025
Sales	1,054.6	846.4	994.2	1,024.1	1,525.3	1,063.2	1,284.4	1,248.3	1,689.8	969.9
Expenses	965.0	829.8	908.1	898.6	1,135.7	911.6	1,031.5	1,029.0	1,273.2	925.6
Operating Profit	89.6	16.6	86.2	125.5	389.6	151.6	252.9	219.3	416.6	44.3
OPM %	8.49%	1.96%	8.67%	12.26%	25.55%	14.26%	19.69%	17.57%	24.66%	4.57%
Other Income	62.9	26.7	89.1	33.1	53.2	36.8	106.4	24.7	39.5	180.9
Interest	33.8	33.8	28.2	17.4	27.7	24.9	30.0	29.2	30.6	23.2
Depreciation	53.0	50.4	50.8	51.6	52.5	51.9	53.6	55.5	61.2	59.4
Profit before tax	65.6	-40.9	96.2	89.7	362.7	111.7	275.7	159.4	364.4	142.6
Tax %	-36.5%	-18.4%	-19.8%	-17.1%	-24.7%	-23.6%	23.8%	25.5%	-23.9%	20.6%
Net Profit	41.7	-33.4	77.2	74.3	273.1	85.3	210.1	118.8	277.3	113.1
EPS in Rs	0.35	-0.28	0.61	0.56	2.06	0.64	1.59	0.9	0	0.85

Metrics	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025
Sales	1,716.0	2,163.6	1,748.9	1,911.4	1,958.6	2,552.4	1,951.1	2,241.8	2,204.2	2,754.1
Expenses	1,628.6	1,812.3	1,616.5	1,645.7	1,690.2	2,022.4	1,746.7	1,900.1	1,866.5	2,193.1
Operating Profit	87.3	351.3	132.3	265.6	268.4	529.9	204.5	341.6	337.7	561.0
OPM %	5.09%	16.24%	7.57%	13.9%	13.7%	20.76%	10.48%	15.24%	15.32%	20.37%
Other Income	82.5	24.5	38.3	49.2	29.2	-4.1	19.5	61.1	12.1	42.0
Interest	94.7	104.3	118.5	109.9	105.9	114.2	107.0	107.6	103.3	103.7
Depreciation	164.4	184.4	173.6	184.5	186.3	196.1	184.6	192.2	196.8	242.8
Profit before tax	-89.2	87.1	-121.5	20.4	37.7	246.0	-67.5	102.9	49.8	256.6
Tax %	18.5%	-51.4%	-7%	-168.9%	-171%	-58.6%	-64.6%	-94.8%	-126.9%	-46.5%
Net Profit	-90.2	50.1	-98.6	5.0	10.1	101.3	-88.6	22.6	3.7	153.5
EPS in Rs	-0.76	0.42	-0.83	0.04	0.08	0.77	-0.67	0.17	0.03	0

Shareholding Distribution

Shareholding Pattern

Compounded Data

Consolidated

Standalone

Compounded Sales Growth
10 Years:	0%
5 Years:	0%
3 Years:	17%
TTM:	20%

Compounded Profit Growth
10 Years:	0%
5 Years:	0%
3 Years:	22%
TTM:	78%

Stock Price CAGR
10 Years:	0%
5 Years:	0%
3 Years:	0%
1 Year:	38%

Compounded Sales Growth
10 Years:	0%
5 Years:	0%
3 Years:	12%
TTM:	12%

Compounded Profit Growth
10 Years:	0%
5 Years:	0%
3 Years:	-38%
TTM:	476%

Stock Price CAGR
10 Years:	0%
5 Years:	0%
3 Years:	0%
1 Year:	38%

All Deals

Date	Stock	Party	Deal	Acq. Mode	Trans.	Quan.	Price	Value

Stock Mutual Funds Data

Order Book

News Date ▲▼	Headline ▲▼	Issuer Entity ▲▼	Issuer Type ▲▼	Order Size ▲▼	Time Period ▲▼
Loading company updates…

Loading technicals…

Moving Averages

Latest Close: — • Records Used: — • Last Trading Date: —

Simple Moving Averages (SMA)

Period	SMA Value	Status

Exponential Moving Averages (EMA)

Period	EMA Value	Status

Oscillators

Key Oscillators

latest calculation

Indicator	Value

PIRAMAL PHARMA

PIRAMAL PHARMA

PIRAMAL PHARMA - Share Price & Details

Broker Recommendations

Price Chart

Volume Chart

Peer Comparison

Peer Comparison Chart

About PIRAMAL PHARMA

Order Book

Latest News

Piramal Pharma - Kaynes Tech, Eternal among 8 F&O stocks that saw a high increase in futures open interest

Piramal Pharma Solutions boosts formulation development at Morpeth site with Korsch XM-12

From Compliance to Commitment: How Piramal Pharma is Reimagining Sustainability in Pharma

Divi’s, Piramal Pharma to Sai Life: Jefferies lists four pharma stocks to buy for up to 30% gains. Do you own any?

A Look At The Fair Value Of Piramal Pharma Limited (NSE:PPLPHARMA)

Piramal Pharma jumps 8%; JM Financial says 'Buy' stock, shares target price

Piramal Pharma Solutions, George Medicines develop new hypertension drug Widaplik

Piramal Pharma Solutions Supports George Medicines in Developing its New Drug for Hypertension, WIDAPLIK™ (telmisartan, amlodipine and indapamide)

Piramal Pharma Solutions supports George Medicines in developing new drug for hypertension

Stocks to buy in 2025 for long term: Global Health, Piramal Pharma among 5 stocks that could give 15-52% return

Piramal Pharma Solutions, NewAmsterdam Pharma open dedicated oral solid dosage form suite at Piramal...

piramal pharma opens usa facility for osd production

Piramal Pharma Solutions makes investment to enhance oral solid dosage production capabilities in US

Piramal Pharma announces Rs 1,626 crore investment in subsidiary; stock ends mildly higher

Piramal Pharma unit infuses ₹1,626 crore into PPL Pharma via preference shares

Piramal Pharma Solutions and NewAmsterdam Pharma Invest in Dedicated Suite to Enhance Oral Solid Dosage Production Capabilities at Piramal's Sellersville, Pennsylvania Site

While institutions own 24% of Piramal Pharma Limited (NSE:PPLPHARMA), private companies are its largest shareholders with 36% ownership

Vishal Bhargava Appointed as Chief Information Officer at Piramal Pharma Ltd - Consumer Products Division

Piramal Pharma Limited (PPLPHARMA) Stock Experiences Sudden Dip - Rapid growth opportunities

Piramal Pharma to Announce Q1FY26 Results on July 28

Piramal Pharma's loss narrows to Rs82 crore in June quarter

Piramal Pharma Limited Announces Results for Q1FY26

US CDMO business seeing softening, says Piramal Pharma Chairperson

Piramal Pharma Limited (543635) Stock Experiences Sudden Dip - Skyrocketing profit margins

Would You Accumulate or Wait on Piramal Pharma Limited (PPLPHARMA) - Breakthrough profit margins

Piramal Pharma Limited (PPLPHARMA) Expands into New Market - Market-beating returns

Piramal Pharma Limited (PPLPHARMA) Quarterly Results Are Out - Unbelievable profit margins

Piramal Pharma Faces Decline Amid Broader Market Gains and Mixed Performance Indicators

Piramal Pharma receives upgrade in LT credit ratings

Piramal Pharma Limited (PPLPHARMA) Hits 52 Week High - Free Capital Allocation Plans

Pharma stock falls over 3% after FII likely to offloads 10% stake worth ₹2700 Cr in the company

Why Investors Shouldn't Be Surprised By Piramal Pharma Limited's (NSE:PPLPHARMA) P/S

Piramal Pharma Solutions breaks ground on $90 mn US expansion

Large-Cap Pharma Stock Under Rs 200: Record Date Set For Final Dividend For This Much Payout; Should You Buy?

Piramal Pharma Limited Expands Integrated Biologics Manufacturing to Meet Rising Pharmaceutical Demand

Piramal Pharma Expands Biologics Manufacturing Infrastructure to Support End-to-End Drug Development

Piramal Pharma Sees Significant Rise in Open Interest Amid Increased Trading Activity

Piramal Pharma Sees Significant Open Interest Surge Amid Dynamic Trading Environment

Piramal Pharma shares gain after Canada unit gets zero observations from USFDA with no action indicated

Piramal Pharma's Canada facility gets zero USFDA observation

From Discovery to Delivery: How Piramal Pharma Limited is Strengthening its Drug Development Capabilities

Piramal Pharma promotes Women’s Health with i-pill Daily Campaign

The market is punishing Piramal Pharma. Is it an overreaction? | Stock Market News

Stocks to buy in 2025: Lupin, Piramal Pharma among 5 stocks that could give 10-20% return

Piramal Pharma Limited Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now

Piramal Pharma to stay away from prescription business in India: Nandini Piramal

Policy Uncertainty in the US Slows Pharma Decisions |

Piramal Pharma reports Q4 FY25 consolidated net profit of Rs. 153.50 Cr

Stock Recommendations Today: Defence, IndusInd Bank, Piramal Pharma On Brokerages Radar

Piramal Pharma Limited Announces Results for Q4 and FY2025

Piramal Pharma Q4 net profit jumps 52% to ₹154 crore; revenue up 8%, dividend declared

Piramal Pharma stock falls 5% after Q4 results; check key numbers here

Piramal Pharma Q4 Review: Operationally Inline; FY25 Ends On A Strong Note, Says Motilal Oswal —Maintains Buy

Piramal Pharma expects single-digit growth in FY26 amid uncertainties

Piramal Pharma Q4 Results Review: Goldman Sachs Highlights Strong Profit Growth Potential

Piramal Pharma to invest $90 million for infra expansion in US amid Trumps America First policy

Piramal Pharma to Expand Two U.S. Sites

Piramal Pharma To Invest $90 Million In US Site Expansions

Piramal Pharma invests $90M for expansion of two US sites

Buy, Sell Or Hold: NTPC Green Energy, Swiggy, Piramal Pharma, CMS Info — Ask Profit

Piramal Pharma Limited's (NSE:PPLPHARMA) last week's 5.6% decline must have disappointed private companies who have a significant stake

Piramal Pharma to conduct board meeting

The Ceiling Breaker: Nandini Piramal, Chairperson, Piramal Pharma Limited (PPL)

Nandini Piramal charts bold growth path: Piramal Pharma eyes $2 billion revenue by FY30

Piramal Pharma Ltd Spurts 3.8%

Piramal Pharma's Mumbai facility gets 6 observations from US FDA inspection

Piramal Pharma Q3 FY25 revenue up 13%

Piramal Pharma Limited Announces Results for Q3 and 9M FY25

Piramal Pharma Shifts to Renewable Biomass Briquettes, Slashes Carbon Footprint